Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York
Assistant Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Director of the Uveal Melanoma Program
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Head of Thoracic Group
Department of Medical Oncology
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for global physicians and other healthcare professionals who care for patients with cancer.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2022, through November 13, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module
Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)
Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)
Downloadable slideset from a text module on systemic therapies for advanced hepatocellular carcinoma, from Clinical Care Options (CCO)